This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Tobira Therapeutics, Inc.
Drug Names(s): RB006 (IV bolus) + RB007 (IV bolus), pegnivacogin/anivamersen, REG1
Description: REG1 consists of an oligonucleotide aptamer anticoagulant (RB006, pegnivacogin) directed against Factor IXa and an oligonucleotide antidote (RB007, anivamersen) that is complementary to a portion of RB006 and binds/neutralizes it. Aptamers are single strands of nucleic acid that adopt a specific shape, allowing them to bind proteins specifically and with high affinity.
Regado licensed the antidote technology from Duke University.
Regado and Archemix
In October 2003, Archemix entered into an agreement with Regado Biosciences for the discovery and development of aptamers. Under the terms of the agreement, Archemix is eligible to receive milestone payments in the aggregate amount of up to approximately $5.5 million per product, contingent upon the achievement of development, regulatory and first commercial sale milestones. In addition, Archemix is entitled to receive a royalty on any net sales of products containing aptamers and 15%, or 25% for products directed toward two specified targets, of all sublicense income received by Regado with respect to the grant of a sublicense to such products.
Regado and Nektar
In December 2006, Regado entered into a license, manufacturing and supply agreement with Nektar pursuant to which Regado obtained an exclusive, worldwide license to certain Nektar-controlled patent rights and...See full deal structure in Biomedtracker
Partners: Archemix Corp. Nektar Therapeutics
Revolixys Kit News
Additional information available to subscribers only: